Aktis Oncology (NASDAQ:AKTS) Shares Down 3.7% – Time to Sell?

Aktis Oncology (NASDAQ:AKTS) traded down 3.7% on Monday . The stock traded as low as $16.71 and last traded at $16.7250. 24,411 shares traded hands during trading, a decline of 93% from the average session volume of 368,978 shares. The stock had previously closed at $17.37.

Analyst Ratings Changes

A number of research firms have issued reports on AKTS. Bank of America initiated coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 price objective on the stock. Leerink Partners began coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 target price for the company. JPMorgan Chase & Co. assumed coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 price target on the stock. TD Cowen began coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They set a “buy” rating on the stock. Finally, HC Wainwright increased their price objective on shares of Aktis Oncology from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $32.00.

Aktis Oncology Stock Up 2.1%

The company has a 50-day simple moving average of $18.75.

Insider Transactions at Aktis Oncology

In other news, Director Helen Susan Kim acquired 835,000 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were bought at an average price of $18.00 per share, with a total value of $15,030,000.00. Following the completion of the purchase, the director directly owned 5,671,825 shares in the company, valued at $102,092,850. This trade represents a 17.26% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm acquired 1,112,777 shares of Aktis Oncology stock in a transaction on Monday, January 12th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $20,029,986.00. Following the completion of the acquisition, the insider directly owned 10,260,064 shares in the company, valued at $184,681,152. This trade represents a 12.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 6,117,776 shares of company stock valued at $110,119,968 in the last ninety days. Corporate insiders own 3.30% of the company’s stock.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.